- Nutriband Inc. (NTRB, Financial) has been included in four major Russell indexes as part of the 2025 reconstitution.
- Projected peak annual U.S. sales for AVERSA Fentanyl range from $80 million to $200 million.
- The Russell indexes collectively benchmark approximately $10.6 trillion in assets.
Nutriband Inc. (NTRB) has achieved a significant milestone by being added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes. This inclusion is part of the 2025 reconstitution of the Russell indexes, which serve as benchmarks for about $10.6 trillion in assets as of June 2024.
The company, based in Orlando, Florida, is focusing on its AVERSA pipeline, particularly the AVERSA Fentanyl product. The projected peak annual U.S. sales for AVERSA Fentanyl are estimated to be between $80 million and $200 million. This innovative product aims to improve the safety profile of medications that are easily abused while ensuring their availability to patients who need them.
The addition of Nutriband to these prestigious indexes is a clear indication of the growing market recognition of the company's potential and the momentum it is building. With FTSE Russell transitioning to a semi-annual reconstitution frequency starting in 2026, Nutriband will need to maintain its qualifying metrics to retain its positions, thereby keeping pressure on management to execute their development strategy effectively.
